Atrium Therapeutics, Inc. - Common Stock (NQ:RNA)

7.970 +0.130 (+1.66%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Atrium Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Why Is Avidity Biosciences Stock Down 20% Pre-market Today? ↗

September 11, 2025

Via Stocktwits

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

September 10, 2025

Via Benzinga

Wednesday's after hours session: top gainers and losers ↗

September 10, 2025

As the regular session of the US market concludes on Wednesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

Avidity Drug Shows Yearlong Gains In Duchenne Muscular Dystrophy Trial ↗

September 10, 2025

Avidity's del-zota treatment improved muscle function, increased dystrophin levels, and reduced damage markers in Duchenne muscular dystrophy after one year.

Via Benzinga

Novartis Reportedly Eyeing To Acquire Avidity Biosciences: But Retail Expects Management To Sell Only At Significant Premium ↗

August 06, 2025

Via Stocktwits

Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks ↗

March 12, 2025

On Tuesday, BMO Capital Markets initiated coverage on Dyne Therapeutics, Inc. (NASDAQ:DYN), focused on developing therapies for ...

Via Benzinga

Avidity Biosciences Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗

February 28, 2025

Via Benzinga

Analyst Expectations For Avidity Biosciences's Future ↗

January 10, 2025

Via Benzinga

Deep Dive Into Avidity Biosciences Stock: Analyst Perspectives (8 Ratings) ↗

September 10, 2025

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

September 09, 2025

Via Benzinga

Avidity Biosciences (NASDAQ:RNA) Exhibits High-Quality Technical Breakout Setup ↗

September 05, 2025

Avidity Biosciences (RNA) stock shows a strong technical breakout setup with high momentum, trading above key moving averages in a bullish trend.

Via Chartmill

Avidity (RNA) Q2 Revenue Jumps 88% ↗

August 07, 2025

Via The Motley Fool

Avidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover Deal ↗

August 06, 2025

The company is focused on treatments for forms of muscular dystrophy.

Via Investor's Business Daily

What 8 Analyst Ratings Have To Say About Avidity Biosciences ↗

December 20, 2024

Via Benzinga

Assessing Avidity Biosciences: Insights From 10 Financial Analysts ↗

November 13, 2024

Via Benzinga

In-Depth Examination Of 10 Analyst Recommendations For Avidity Biosciences ↗

October 21, 2024

Via Benzinga

Veritex Holdings, Sequans Communications, Canaan And Other Big Stocks Moving Higher On Monday ↗

July 14, 2025

Via Benzinga

Expert Outlook: Avidity Biosciences Through The Eyes Of 11 Analysts ↗

June 27, 2025

Via Benzinga

The Analyst Verdict: Avidity Biosciences In The Eyes Of 12 Experts ↗

June 10, 2025

Via Benzinga

Avidity Biosciences Touts Encouraging Functional Gains And Biomarker Reductions In Rare Muscular Weakness Disease Trial ↗

June 09, 2025

Avidity shares early del-brax FSHD data showing improved mobility, strength, and safety; Phase 3 FORWARD trial now underway.

Via Benzinga

12 Analysts Assess Avidity Biosciences: What You Need To Know ↗

May 07, 2025

Via Benzinga

Evaluating Avidity Biosciences: Insights From 10 Financial Analysts ↗

October 21, 2024

Via Benzinga

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost ↗

April 21, 2025

The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly.

Via Investor's Business Daily

Topics Government

Beyond The Numbers: 13 Analysts Discuss Avidity Biosciences Stock ↗

April 09, 2025

Via Benzinga

Forecasting The Future: 13 Analyst Projections For Avidity Biosciences ↗

March 18, 2025

Via Benzinga

Avidity Biosciences Touts Positive Data From Early-Stage Duchenne Muscular Dystrophy Study Data, FDA Submission Expected By End Of 2025 ↗

March 17, 2025

Avidity's del-zota met key Phase 1/2 trial goals in DMD44, shows strong exon skipping, dystrophin restoration and creatine kinase reduction.

Via Benzinga

This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

March 12, 2025

Via Benzinga

Topics Stocks

Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic ↗

January 03, 2025

William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport vehicle platform and promising therapies for neurodegenerative diseases.

Via Benzinga

This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

December 20, 2024

Via Benzinga

Topics Stocks

Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News ↗

November 13, 2024

The company is now pivoting its technology to the cardiovascular space under a partnership with Bristol Myers Squibb.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.